Back to search

Netherlands· NL-d567a71e5653

Pyrazinamide CF 500 mg, tabletten

A pyrazinamide product containing pyrazinamide, registered in Netherlands by Centrafarm B.V.. The same ATC class is registered in 14 of our 19 countries.

ATC J04AK01

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedPyrazinamide CF 500 mg, tablettenATCJ04AK01REGISTER NO.NL-d567a71e5653PACKS LISTED1CHECKEDSeptember 29, 2026

Where it is registered

Pyrazinamide is registered in 14 of 19 countries.

Countries holding a registration under ATC J04AK01 (pyrazinamide), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 8 of them publish a price we can compare per daily dose

Pyrazinamide · ATC J04AK01

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of pyrazinamide costs, country by country.

Normalised to the WHO defined daily dose (1.5 g), the median price runs from $0.61 in France to $3.20 in Switzerland — a ×5.2 gap.

  • 2 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Pyrazinamide · price per daily dose (1.5 g)

USD · FX 28 Sept 2026

  • CH Switzerland$3.20
  • FR France$0.61
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)
Active substance
PYRAZINAMIDE
Manufacturer
Centrafarm B.V.
Country
Netherlands (NL)
ATC code
J04AK01
ATC class
Pyrazinamide
Defined daily dose
1.5 g, O
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    50772

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

81 interactions on record for pyrazinamide.

Graded by severity as the source publishes them — 4 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Pyrazinamide · interactions on record

81 records

  • 4 severe
  • 19 moderate
  • 54 info

Most severe, free to view

  • LeflunomidL04AA13severe
  • TeriflunomidL04AA31severe
  • LeflunomideL04AK01severe
  • TeriflunomideL04AK02severe

4 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Pyrazinamide in 12 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All pyrazinamide products

Authorised across Europe · EMA

The same active substance is authorised in 19 EEA countries. Names it is sold under:

  • Austria · Pyrafat
  • Belgium · Tebrazid
  • Bulgaria · Пиразинамид Крка
  • Germany · Pyrafat, Pyrazinamid Jenapharm
  • Denmark · Pyrazinamid Sad
  • Spain · Pirazinamida Prodes
  • Finland · Tisamid
  • France · Pirilene
  • United Kingdom (Northern Ireland) · Pyrazinamide Morningside Healthcare
  • Greece · Pyrazinamide Genepharm
  • Croatia · Pyrazinamid Krka
  • Lithuania · Pyrafat, Pyrazinamide Krka
  • Luxembourg · Tebrazid
  • Latvia · Pyrazinamide Olpha
  • Malta · Pyrazinamide Morningside Healthcare
  • Poland · Pyrazinamid Farmapol
  • Portugal · Pramide
  • Romania · Pirazinamida Atb
  • Slovenia · Pirazinamid Krka

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/ff958f5f-9833-4f12-bcf3-63a62a19717b
GET /v1/drugs/ff958f5f-9833-4f12-bcf3-63a62a19717b?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tablet",
  "route": "Oraal gebruik",
  "soort": "RVG",
  "source": "cbg_meb",
  "smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h50772_smpc.pdf",
  "strength": null,
  "atc_label": "Pyrazinamide",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg50772",
  "excipients": [
    "AARDAPPELZETMEEL",
    "CARMELLOSE NATRIUM (E 466)",
    "MAGNESIUMSTEARAAT (E 470b)",
    "POVIDON K 90 (E 1201)",
    "SILICIUMDIOXIDE (E 551)",
    "TALK (E 553b)"
  ],
  "substances": [
    "PYRAZINAMIDE"
  ],
  "leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h50772.pdf",
  "authorised_at": "1992/09/30",
  "procedure_number": null,
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "50772",
  "additional_monitoring": "N"
}

See everything about pyrazinamide.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.